1. Home
  2. EVO vs DFIN Comparison

EVO vs DFIN Comparison

Compare EVO & DFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVO
  • DFIN
  • Stock Information
  • Founded
  • EVO 1993
  • DFIN 1983
  • Country
  • EVO Germany
  • DFIN United States
  • Employees
  • EVO N/A
  • DFIN N/A
  • Industry
  • EVO Biotechnology: Pharmaceutical Preparations
  • DFIN Other Consumer Services
  • Sector
  • EVO Health Care
  • DFIN Consumer Discretionary
  • Exchange
  • EVO Nasdaq
  • DFIN Nasdaq
  • Market Cap
  • EVO 1.4B
  • DFIN 1.4B
  • IPO Year
  • EVO 2021
  • DFIN N/A
  • Fundamental
  • Price
  • EVO $4.15
  • DFIN $45.01
  • Analyst Decision
  • EVO Strong Buy
  • DFIN Strong Buy
  • Analyst Count
  • EVO 1
  • DFIN 3
  • Target Price
  • EVO $7.00
  • DFIN $70.67
  • AVG Volume (30 Days)
  • EVO 42.9K
  • DFIN 321.7K
  • Earning Date
  • EVO 11-05-2025
  • DFIN 10-29-2025
  • Dividend Yield
  • EVO N/A
  • DFIN N/A
  • EPS Growth
  • EVO N/A
  • DFIN N/A
  • EPS
  • EVO N/A
  • DFIN 1.12
  • Revenue
  • EVO $912,894,891.00
  • DFIN $750,800,000.00
  • Revenue This Year
  • EVO N/A
  • DFIN N/A
  • Revenue Next Year
  • EVO $10.78
  • DFIN $4.66
  • P/E Ratio
  • EVO N/A
  • DFIN $39.62
  • Revenue Growth
  • EVO N/A
  • DFIN N/A
  • 52 Week Low
  • EVO $2.84
  • DFIN $37.80
  • 52 Week High
  • EVO $5.64
  • DFIN $69.93
  • Technical
  • Relative Strength Index (RSI)
  • EVO 63.61
  • DFIN 30.62
  • Support Level
  • EVO $4.05
  • DFIN $44.17
  • Resistance Level
  • EVO $4.27
  • DFIN $55.35
  • Average True Range (ATR)
  • EVO 0.09
  • DFIN 2.28
  • MACD
  • EVO 0.01
  • DFIN -0.71
  • Stochastic Oscillator
  • EVO 73.91
  • DFIN 6.99

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

About DFIN Donnelley Financial Solutions Inc.

Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.

Share on Social Networks: